• Product NameeNOS (Phospho-Ser615) Conjugated Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• Species ReactivityHu Ms Rt
• SpecificityThe antibody detects endogenous levels of eNOS only when phosphorylated at serine 615.
• Immunogen DescriptionPeptide sequence around phosphorylation site of serine 615 (F-N-S(p)-I-S) derived from Human eNOS.
• ConjugatesBiotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
• Excitation EmissionAF350: 346nm/442nm
  AF405: 401nm/421nm
  AF488: 493nm/519nm
  AF555: 555nm/565nm
  AF594: 591nm/614nm
  AF647: 651nm/667nm
  AF680: 679nm/702nm
  AF750: 749nm/775nm
• Alternative Names    Constitutive NOS, EC 1.14.13.39, EC-NOS, ECNOS, Endothelial NOS, NOS, type III, NOS3, NOSIII, Nitric-oxide synthase, endothelial, cNOS
• Accession No. Swiss-Prot#:P29474
  NCBI Gene ID:4846
  
• UniprotP29474
• Gene ID4846;
• Calculated MW 140
• Formulation 0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
• Storage Store at 4˚C in dark for 6 months

• Suggested Dilution:
  AF350 conjugated: most applications: 1: 50 - 1: 250
  AF405 conjugated: most applications: 1: 50 - 1: 250
  AF488 conjugated: most applications: 1: 50 - 1: 250
  AF555 conjugated: most applications: 1: 50 - 1: 250
  AF594 conjugated: most applications: 1: 50 - 1: 250
  AF647 conjugated: most applications: 1: 50 - 1: 250
  AF680 conjugated: most applications: 1: 50 - 1: 250
  AF750 conjugated: most applications: 1: 50 - 1: 250
  Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

• Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting